WuXi Biologics is expected to deliver faster sales growth and higher margins this year. Click here to find out why I upgraded ...

The global biologics contract development and manufacturing organization (cdmo) market size is estimated to grow by USD 16.32 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hong Kong stocks rebounded from a four-month low after China’s securities regulator pledged to stabilise the market after a wobbly start to the year. The Hang Seng Index rose 1.4 per cent to 19,141.13 ...

WuXi AppTec announced late yesterday that the Shanghai-based company had pared its stake in WuXi XDC Cayman through two block ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

CHMP has granted Eisai Europe and Biogen a positive opinion for the use of their monoclonal antibody therapy in treating early Alzheimer’s disease.

JPMorgan upgraded Wuxi Biologics (WXXWY) to Overweight from Neutral with a price target of HK$20, up from HK$13, citing expected order growth and improved margins. Although the newsthat WuXi Bio ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would limit business for Chinese biotech companies ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks to enhance its margins while continuing to navigate geopolitical tensions.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...